中性粒细胞与淋巴细胞比值及鳞状细胞癌抗原预测宫颈鳞状细胞癌患者预后价值分析

doi:10.12280/gjfckx.20200490

摘要/Abstract

摘要：

宫颈癌是全世界第二大常见妇科恶性肿瘤,每年约50万新诊断病例和27.5万死亡病例,近三分之一的宫颈癌患者死于疾病复发或疾病进展,其中鳞状细胞癌是宫颈癌最常见的细胞类型,其治疗方式有手术、放化疗等。目前宫颈鳞状细胞癌的预后评价常根据术后病理指标,多项研究表明治疗前外周血中性粒细胞与淋巴细胞比值（NLR）对经过放射治疗的宫颈鳞状细胞癌患者的预后影响突出,而血清鳞状细胞癌抗原（SCC-Ag）水平对宫颈鳞状细胞癌患者的复发、生存和淋巴结转移有预测作用,两者作为血液学指标易获取,相对于国际妇产科联盟（FIGO）肿瘤分期等反映肿瘤局部状态,其能更好地反映患者全身状态,从诊断之初即可动态监测,成为临床医生为患者提供最佳诊疗方案的参考因素。现通过阐明NLR和SCC-Ag各自对宫颈鳞状细胞癌预后预测价值的研究现状,以期为宫颈鳞状细胞癌的预后分析开拓一种新思路。

关键词: 宫颈肿瘤, 癌,鳞状细胞, 中性白细胞, 淋巴细胞, 抗原,肿瘤, 预后

Abstract:

Cervical cancer is the second most common gynecological malignancy in the world, causing about 500 000 new diagnoses and 275 000 deaths each year. Nearly one-third of cervical cancer deaths are due to disease recurrence or progression. Squamous cell carcinoma is the most common type of cervical cancer. The treatment of squamous cell cervical cancer includes surgery, chemoradiotherapy and so on. And most of the known prognostic factors of squamous cell cervical cancer are evaluated after operation. Survival studies showed that the ratio of neutrophils to lymphocytes (NLR) in peripheral blood before treatment had a significant influence on the prognosis of patients with squamous cell cervical cancer after radiotherapy. And the serum squamous cell carcinoma antigen (SCC-Ag) level had a predictive effect on the recurrence, survival and lymph node metastasis of patients with squamous cell cervical cancer. NLR and SCC-Ag in peripheral blood can be easily obtained as hematological indexes. Compared with the local state of cancer reflected by International Federation of Gynecology and Obstetrics (FIGO) stage, they can better reflect the general state of patients. Also, they can be dynamically monitored from the beginning of diagnosis, which becomes reference factors for clinicians to provide the best diagnosis and treatment for patients. By elucidating the predictive value of NLR and SCC-Ag in the prognosis of cervical squamous cell carcinoma, it is expected to create a new way to analysis the progression of cervical squamous cell carcinoma.

Key words: Uterine cervical neoplasms, Carcinoma,squamous cell, Neutrophils, Lymphocytes, Antigens,neoplasm, Prognosis

鲁鹏, 候丽盈, 刘艳, 孙树, 李佩玲. 中性粒细胞与淋巴细胞比值及鳞状细胞癌抗原预测宫颈鳞状细胞癌患者预后价值分析[J]. 国际妇产科学杂志, 2021, 48(1): 51-55.

LU Peng, HOU Li-ying, LIU Yan, SUN Shu, LI Pei-ling. The Prognostic Value of the Ratio of Neutrophils to Lymphocytes and Squamous Cell Carcinoma Antigen in Patients with Cervical Squamous Cell Carcinoma[J]. Journal of International Obstetrics and Gynecology, 2021, 48(1): 51-55.

参考文献 40

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Charakorn C, Thadanipon K, Chaijindaratana S, et al. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis[J]. Gynecol Oncol, 2018,150(1):190-200. doi: 10.1016/j.ygyno.2018.03.056. doi: 10.1016/j.ygyno.2018.03.056 pmid: 29606483
[3]	Matsuo K, Mandelbaum RS, Machida H, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix[J]. J Gynecol Oncol, 2018,29(6):e91. doi: 10.3802/jgo.2018.29.e91. doi: 10.3802/jgo.2018.29.e91 pmid: 30207099
[4]	Chen K, Zhan MX, Hu BS, et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma[J]. Oncol Lett, 2018,15(1):315-323. doi: 10.3892/ol.2017.7291. doi: 10.3892/ol.2017.7291 pmid: 29285194
[5]	Rashtak S, Ruan X, Druliner BR, et al. Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer[J]. Clin Colorectal Cancer, 2017, 16(2):115-123.e3. doi: 10.1016/j.clcc.2017.01.008. doi: 10.1016/j.clcc.2017.01.008 pmid: 28365393
[6]	Ceran MU, Tasdemir U, Colak E, et al. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis[J]. J Ovarian Res, 2019,12(1):16. doi: 10.1186/s13048-019-0491-7. doi: 10.1186/s13048-019-0491-7 pmid: 30744662
[7]	Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies[J]. Mol Cancer, 2017,16(1):137. doi: 10.1186/s12943-017-0707-7. doi: 10.1186/s12943-017-0707-7 pmid: 28810877
[8]	Nie W, Yu T, Sang Y, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment[J]. Biochem Biophys Res Commun, 2017,482(4):1400-1406. doi: 10.1016/j.bbrc.2016.12.048. doi: 10.1016/j.bbrc.2016.12.048 pmid: 27956175
[9]	Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008,454(7203):436-444. doi: 10.1038/nature07205. doi: 10.1038/nature07205 pmid: 18650914
[10]	Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies[J]. Cancer Treat Rev, 2017,58:1-13. doi: 10.1016/j.ctrv.2017.05.005. doi: 10.1016/j.ctrv.2017.05.005 pmid: 28602879
[11]	Bao Y, Zhang S, Niyazi H,et al. Abstract LB-057: The expression level and prognostic value of PD-L1 and PD-1 in cervical carcinoma patients[J]. Cancer Research, 2017, 77(Suppl 13):LB-057. doi: 10.1158/1538-7445.AM2017-LB-057.
[12]	黄培坚, 潘志锋, 苏鸿凯. 联合CRP/ALB比值和NLR对宫颈鳞状细胞癌预后的评估价值[J]. 转化医学杂志, 2019,8(2):85-88. doi: 10.3969/j.issn.2095-3097.2019.02.005.
[13]	Lee YY, Choi CH, Kim HJ, et al. Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma[J]. Anticancer Res, 2012,32(4):1555-1561.
[14]	Wu J, Chen M, Liang C, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review[J]. Oncotarget, 2017,8(8):13400-13412. doi: 10.18632/oncotarget.14541. doi: 10.18632/oncotarget.14541 pmid: 28077792
[15]	Huang QT, Man QQ, Hu J, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies[J]. Oncotarget, 2017,8(10):16755-16764. doi: 10.18632/oncotarget.15157. doi: 10.18632/oncotarget.15157 pmid: 28187430
[16]	Ida N, Nakamura K, Saijo M, et al. Prognostic nutritional index as a predictor of survival in patients with recurrent cervical cancer[J]. Mol Clin Oncol, 2018,8(2):257-263. doi: 10.3892/mco.2017.1508. doi: 10.3892/mco.2017.1508 pmid: 29435286
[17]	Wang L, Jia J, Lin L, et al. Predictive value of hematological markers of systemic inflammation for managing cervical cancer[J]. Oncotarget, 2017,8(27):44824-44832. doi: 10.18632/oncotarget.14827. doi: 10.18632/oncotarget.14827 pmid: 28148894
[18]	Zhang Y, Wang L, Liu Y, et al. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery[J]. Int J Gynecol Cancer, 2014,24(7):1319-1325. doi: 10.1097/IGC.0000000000000219. doi: 10.1097/IGC.0000000000000219
[19]	Nuchpramool P, Hanprasertpong J. Preoperative Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Not Clinically Useful in Predicting Prognosis in Early Stage Cervical Cancer[J]. Surg Res Pract, 2018,2018:9162921. doi: 10.1155/2018/9162921. doi: 10.1155/2018/9162921 pmid: 30631798
[20]	Mizunuma M, Yokoyama Y, Futagami M, et al. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer[J]. Int J Clin Oncol, 2015,20(5):989-996. doi: 10.1007/s10147-015-0807-6. doi: 10.1007/s10147-015-0807-6 pmid: 25736530
[21]	魏晓强, 王俊杰, 唐猛. 中性粒细胞与淋巴细胞比值评估老年中晚期宫颈鳞状细胞癌患者同步放化疗的疗效及预后的价值[J]. 中国癌症防治杂志, 2019,11(5):403-407. doi: 10.3969/j.issn.1674-5671.2019.05.08.
[22]	Onal C, Guler OC, Yildirim BA. Prognostic Use of Pretreatment Hematologic Parameters in Patients Receiving Definitive Chemoradiotherapy for Cervical Cancer[J]. Int J Gynecol Cancer, 2016,26(6):1169-1175. doi: 10.1097/IGC.0000000000000741. doi: 10.1097/IGC.0000000000000741 pmid: 27206286
[23]	Jeong MH, Kim H, Kim TH, et al. Prognostic significance of pretreatment lymphocyte percentage and age at diagnosis in patients with locally advanced cervical cancer treated with definite radiotherapy[J]. Obstet Gynecol Sci, 2019,62(1):35-45. doi: 10.5468/ogs.2019.62.1.35. doi: 10.5468/ogs.2019.62.1.35 pmid: 30671392
[24]	Ethier JL, Desautels DN, Templeton AJ, et al. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis[J]. Gynecol Oncol, 2017,145(3):584-594. doi: 10.1016/j.ygyno.2017.02.026. doi: 10.1016/j.ygyno.2017.02.026 pmid: 28222899
[25]	Haraga J, Nakamura K, Omichi C, et al. Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy[J]. Mol Clin Oncol, 2016,5(5):567-574. doi: 10.3892/mco.2016.1028. doi: 10.3892/mco.2016.1028 pmid: 27900086
[26]	Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma[J]. Cancer, 1977,40(4):1621-1628. doi: 10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i. doi: 10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i pmid: 332328
[27]	Markovina S, Wang S, Henke LE, et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer[J]. Br J Cancer, 2018,118(1):72-78. doi: 10.1038/bjc.2017.390. doi: 10.1038/bjc.2017.390 pmid: 29112685
[28]	Fu J, Wang W, Wang Y, et al. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer[J]. Radiat Oncol, 2019,14(1):146. doi: 10.1186/s13014-019-1355-4. doi: 10.1186/s13014-019-1355-4 pmid: 31416463
[29]	Guo Q, Zhu J, Wu Y, et al. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study[J]. Eur J Surg Oncol, 2020,46(1):131-138. doi: 10.1016/j.ejso.2019.08.021. doi: 10.1016/j.ejso.2019.08.021 pmid: 31481274
[30]	Li D, Xu X, Yan D, et al. Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy[J]. J Int Med Res, 2020,48(4):300060519889741. doi: 10.1177/0300060519889741. doi: 10.1177/0300060519889741 pmid: 31889461
[31]	Choi KH, Lee SW, Yu M, et al. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis[J]. J Gynecol Oncol, 2019,30(1):e1. doi: 10.3802/jgo.2019.30.e1. doi: 10.3802/jgo.2019.30.e1 pmid: 30479085
[32]	Oh J, Bae JY. Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance[J]. Obstet Gynecol Sci, 2018,61(3):337-343. doi: 10.5468/ogs.2018.61.3.337. doi: 10.5468/ogs.2018.61.3.337 pmid: 29780775
[33]	Lee YJ, Kim DY, Lee SW, et al. A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection[J]. Gynecol Oncol, 2017,144(3):536-540. doi: 10.1016/j.ygyno.2017.01.001. doi: 10.1016/j.ygyno.2017.01.001 pmid: 28108027
[34]	Zigras T, Lennox G, Willows K, et al. Early Cervical Cancer: Current Dilemmas of Staging and Surgery[J]. Curr Oncol Rep, 2017,19(8):51. doi: 10.1007/s11912-017-0614-5. doi: 10.1007/s11912-017-0614-5 pmid: 28664470
[35]	关德凤, 陈思璐, 陈葛舒逸, 等. ⅠB~ⅡB期宫颈癌盆腔淋巴结转移的影响因素分析[J]. 国际妇产科学杂志, 2019,46(4):462-465. doi: 10.3969/j.issn.1674-1870.2019.04.024.
[36]	Xu F, Li Y, Fan L, et al. Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage[J]. J Cancer, 2018,9(9):1660-1666. doi: 10.7150/jca.24049. doi: 10.7150/jca.24049 pmid: 29760805
[37]	李秀芳, 马媛, 林丽红, 等. 宫颈癌淋巴结转移风险的临床及预后分析[J]. 现代肿瘤医学, 2015,23(10):1424-1427. doi: 10.3969/j.issn.1672-4992.2015.10.30.
[38]	Xu D, Wang D, Wang S, et al. Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis[J]. Int J Gynecol Cancer, 2017,27(9):1935-1942. doi: 10.1097/IGC.0000000000001112. doi: 10.1097/IGC.0000000000001112 pmid: 28914639
[39]	Yang H, Hu H, Gou Y, et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma[J]. Int J Clin Oncol, 2018,23(2):321-328. doi: 10.1007/s10147-017-1210-2. doi: 10.1007/s10147-017-1210-2 pmid: 29101499
[40]	Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy[J]. Cancer, 2019,125(1):127-134. doi: 10.1002/cncr.31778. doi: 10.1002/cncr.31778 pmid: 30329148